The efficacy and safety of Delphini Acne Control in the treatment of mild severity of acne vulgaris: a non-inferiority randomized-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230809001

Enrollment

Registered

2023-08-09

Start date

2023-06-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with mild acne Acne

Interventions

A gel formulation with Bakuchiol and Salicylic acid known for having good exfoliating properties as well as synergistic anti-microbial effects. The formulation also includes snail secretion extract to

Active Comparator Other,Active Comparator Drug

Delphini Acne Control Cream,0.025 tretinoin

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Healthy patients with mild acne

Exclusion criteria

Exclusion criteria: On oral or topical acne medication On oral contraceptive pills On oral medication that have systemic hormonal effect e.g. finasteride, dutasteride, spironolactone

Design outcomes

Primary

Measure	Time frame
Acne lesion count baseline, 4 weeks, 8 weeks, 12 weeks Count	—

Secondary

Measure	Time frame
Skin Hydration baseline, 4 weeks, 8 weeks, 12 weeks Corneometer,Transepidermal Water Loss (TEWL) baseline, 4 weeks, 8 weeks, 12 weeks Tewameter,Skin Sebum level baseline, 4 weeks, 8 weeks, 12 weeks Sebumeter	—

Countries

Thailand

Contacts

Public ContactChanat Kumtornrut

Faculty of Medicine, Chulalongkorn University

chanat_1@yahoo.com66814594965

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026